Blockchain Registration Transaction Record
Aditxt Validates Autoimmune Therapy Candidate ADI-100, Plans Regulatory Filings for Clinical Trials in 2025
Aditxt announces successful preclinical findings for ADI-100, showcasing its potential to induce immune tolerance in autoimmune conditions. Regulatory filings planned for 2025 mark progress towards clinical trials, offering hope for those with autoimmune diseases.

This news showcases the promising potential of Aditxt's lead autoimmune therapy candidate, offering hope for those with autoimmune conditions like type 1 diabetes. The validation of ADI-100's immune tolerance induction represents a significant step towards developing innovative health solutions.
Blockchain | Details |
---|---|
Contract Address | 0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71 |
Transaction ID | 0x7506c4f626ac86fb57bcae2b22a732b4132fb20f50cfc8810eb4905dbbf69644 |
Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
Chain | polygon-main |
NewsRamp Digital Fingerprint | glueGqwp-05b186a75204ef8fdc26ecf1b051ea44 |